A Phase I/II Study of Lintuzumab-Ac225 in Older Patients With Untreated Acute Myeloid Leukemia
Phase of Trial: Phase I/II
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Lintuzumab Ac-225 (Primary) ; Cytarabine; Furosemide; Spironolactone
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Actinium Pharmaceuticals
- 15 Jun 2017 According to an Actinium Pharmaceuticals media release, currently there are twelve active clinical trial sites in this clinical trial.
- 15 Jun 2017 According to an Actinium Pharmaceuticals media release, interim data is expected in the second half of 2017.
- 26 May 2017 Planned End Date changed from 1 May 2017 to 1 Feb 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History